Cullinan Therapeutics
Yue Zhang is a seasoned professional in clinical research and development, currently serving as the Director, Clinical Research Scientist at Cullinan Oncology since February 2023. Prior experience includes directing clinical development at Repertoire Immune Medicines, leading solid tumor strategy at Karyopharm Therapeutics, and serving as a Solid Tumor MSL at AbbVie, where expertise contributed to the formulation of clinical and commercial strategies for oncology assets. Zhang's background also includes significant roles at EMD Serono as a Principal Scientist focusing on clinical biomarkers, and at AstraZeneca as a Senior Scientist managing drug discovery activities and patient stratification strategies. Early career experience includes a postdoctoral fellowship at Novartis, where novel regulatory mechanisms related to Wnt signaling were explored, resulting in publications in prominent scientific journals. Academic credentials include a Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and a B.S. in Biological Science from Peking University.
This person is not in the org chart
Cullinan Therapeutics
1 followers
Cullinan Therapeutics is dedicated to creating new standards of care for patients. We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications.